CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting

WAL Investor News: If You Have Suffered Losses in Western Alliance Bancorporation (NYSE: WAL), You Are Encouraged to Contact The Rosen Law...

Global Times: Xi Jinping Thought on Economy guides long-term steady economic growth for China: Jin Sheping

HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List and Inclusion in the First Commercial Insurance Drug List in China

ALLUONE Launches IoT-Based Home Smart Garden 'Watering Garden'

RESPIREE SECURES SINGAPORE HSA APPROVAL FOR ITS AI-ENABLED 1BIO™AI SOFTWARE TO SUPPORT ACUTE DETERIORATION DETECTION

AI-for-Science Startup ChemLex Raises USD 45M, Launching Self-Driving Lab for Drug Discovery in Singapore

Linux Foundation Welcomes Mitsubishi Electric as Gold Member During Open Source Summit Japan

Linux Foundation Research Releases New Report: "The State of Open Source Japan 2025: Accelerating Business Value through Strategic Open...

Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December...

Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially...

Matthews International Provides Update on Actions to Create Shareholder Value and Addresses Director Nominations

SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025

Anchorage Digital Integrates Middleware Provider BridgePort to Enhance Institutional Settlement Infrastructure

Lime & Lemon Apex Redefines the Dining Scene with an Experience the Triangle Was Waiting For

ImCheck Reports Durable Responses and Early Overall Survival Signal with ICT01 in First-line AML at ASH 2025

Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at...

Former National Security Analyst Signals a Warning in Recent Presentation: “Most Americans are completely uninformed about China’s ambition...

Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)